LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

Search

Celsion Corp

Aperta

0

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

Massimo

Metriche Chiave

By Trading Economics

Dipendenti

25

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+1650% upside

Dividendi

By Dow Jones

Utili prossimi

13 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

7.2M

18M

Apertura precedente

0

Chiusura precedente

0

Celsion Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

26 giu 2025, 23:49 UTC

Utili

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

26 giu 2025, 22:19 UTC

Acquisizioni, Fusioni, Takeovers

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

26 giu 2025, 21:30 UTC

Utili

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

26 giu 2025, 21:07 UTC

Utili

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

26 giu 2025, 23:49 UTC

Discorsi di Mercato

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

26 giu 2025, 23:39 UTC

Discorsi di Mercato

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

26 giu 2025, 23:34 UTC

Acquisizioni, Fusioni, Takeovers

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

26 giu 2025, 23:33 UTC

Acquisizioni, Fusioni, Takeovers

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

26 giu 2025, 23:32 UTC

Acquisizioni, Fusioni, Takeovers

Wesfarmers Will No Longer Receive Earnings From BWP Management

26 giu 2025, 23:32 UTC

Acquisizioni, Fusioni, Takeovers

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

26 giu 2025, 23:31 UTC

Acquisizioni, Fusioni, Takeovers

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

26 giu 2025, 23:31 UTC

Acquisizioni, Fusioni, Takeovers

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

26 giu 2025, 23:30 UTC

Acquisizioni, Fusioni, Takeovers

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

26 giu 2025, 23:29 UTC

Acquisizioni, Fusioni, Takeovers

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

26 giu 2025, 23:19 UTC

Acquisizioni, Fusioni, Takeovers

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

26 giu 2025, 22:06 UTC

Utili

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 giu 2025, 21:15 UTC

Utili

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

26 giu 2025, 21:07 UTC

Acquisizioni, Fusioni, Takeovers

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

26 giu 2025, 21:07 UTC

Acquisizioni, Fusioni, Takeovers

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

26 giu 2025, 21:07 UTC

Acquisizioni, Fusioni, Takeovers

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

26 giu 2025, 21:07 UTC

Utili

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 giu 2025, 21:06 UTC

Acquisizioni, Fusioni, Takeovers

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

26 giu 2025, 21:06 UTC

Acquisizioni, Fusioni, Takeovers

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

26 giu 2025, 21:06 UTC

Discorsi di Mercato

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

26 giu 2025, 21:05 UTC

Acquisizioni, Fusioni, Takeovers

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 giu 2025, 21:05 UTC

Acquisizioni, Fusioni, Takeovers

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 giu 2025, 20:52 UTC

Utili

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

26 giu 2025, 20:51 UTC

Utili

Correct: Nike 4Q Net $211M, Not $200M >NKE

26 giu 2025, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

26 giu 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Celsion Corp Previsione

Obiettivo di Prezzo

By TipRanks

1650% in crescita

Previsioni per 12 mesi

Media 14 USD  1650%

Alto 14 USD

Basso 14 USD

Basato su 2 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Celsion Corp - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

2 ratings

1

Acquista

1

Mantieni

0

Vendi

Notizie finanziarie

$

Chi Siamo Celsion Corp

Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.